Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q3 results

- PMLiVE

Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

The BTD is based on data from the phase 2 TRAILBLAZER-ALZ study in early symptomatic Alzheimer's patients

- PMLiVE

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021

- PMLiVE

Stick or Twist? Healthcare brands in a (post) COVID-19 world

How have our perceptions of healthcare brands and our purchasing habits changed during the COVID-19 pandemic?

Say Communications

- PMLiVE

US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns

Laboratory analyses found the therapy was not effective against variants first discovered in South Africa and Brazil

Biogen Idec building

Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval

Confirmatory trial is planned to be completed ahead of nine-year time frame

- PMLiVE

Oxford University to study antiparasitic drug ivermectin in COVID-19 trial

The potential COVID-19 treatment will be investigated as part of the large-scale PRINCIPLE trial

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

- PMLiVE

Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome

TNX-102 is already in phase 3 development for the treatment of fibromyalgia

- PMLiVE

Gilead reveals real-world data for COVID-19 drug Veklury

Veklury significantly lowered the risk of mortality compared with matched controls in real-world analysis, says Gilead

- PMLiVE

Court rules on AZ and EU’s COVID-19 vaccine dispute

The Court in Brussels has ordered AZ to deliver a total of 80.2 million doses to the EU by 27 September 2021

- PMLiVE

US announces $3bn funding boost for antiviral COVID-19 treatments

Funding will go towards the discovery, development and manufacturing of antiviral medicines

- PMLiVE

Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

Vaccine candidate failed to meet prespecified measure of statistical success in clinical trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links